Showing results (511-520 of 13,202) with videos related to

Sort By:
Pageof 1,321
Diabetes Care|April 22, 2020
Effects of Continuous Glucose Monitoring on Metrics of Glycemic Control in Diabetes: A Systematic Review With Meta-analysis of Randomized Controlled TrialsMaria Ida Maiorino, Simona Signoriello, Antonietta Maio, et al.
Diabetes Care|April 22, 2020
Sex Disparities in Cardiovascular Outcome Trials of Populations With Diabetes: A Systematic Review and Meta-analysisKristin K Clemens, Mark Woodward, Bruce Neal, et al.
Diabetes Care|April 17, 2020
Metabolic Factors, Lifestyle Habits, and Possible Polyneuropathy in Early Type 2 Diabetes: A Nationwide Study of 5,249 Patients in the Danish Centre for Strategic Research in Type 2 Diabetes (DD2) CohortDiana H Christensen, Søren T Knudsen, Sandra S Gylfadottir, et al.
Diabetes Care|April 30, 2020
Acrylamide Exposure and Oxidative DNA Damage, Lipid Peroxidation, and Fasting Plasma Glucose Alteration: Association and Mediation Analyses in Chinese Urban AdultsBin Wang, Weihong Qiu, Shijie Yang, et al.
Diabetes Care|April 30, 2020
Early Metabolic Features of Genetic Liability to Type 2 Diabetes: Cohort Study With Repeated Metabolomics Across Early LifeJoshua A Bell, Caroline J Bull, Marc J Gunter, et al.
Diabetes Care|October 27, 2019
Oxidatively Damaged DNA/RNA and 8-Isoprostane Levels Are Associated With the Development of Type 2 Diabetes at Older Age: Results From a Large Cohort StudyBen Schöttker, Yang Xuan, Xīn Gào, et al.
Diabetes Care|August 17, 2016
Genetic Predictors of Cardiovascular Mortality During Intensive Glycemic Control in Type 2 Diabetes: Findings From the ACCORD Clinical TrialHetal S Shah, He Gao, Mario Luca Morieri, et al.
Diabetes Care|August 17, 2016
Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized TrialJulio Rosenstock, Ronnie Aronson, George Grunberger, et al.
Diabetes Care|August 14, 2016
Endoscopic Duodenal Mucosal Resurfacing for the Treatment of Type 2 Diabetes: 6-Month Interim Analysis From the First-in-Human Proof-of-Concept StudyHarith Rajagopalan, Alan D Cherrington, Christopher C Thompson, et al.
Diabetes Care|May 15, 2021
Frequency of Autoantibody-Negative Type 1 Diabetes in Children, Adolescents, and Young Adults During the First Wave of the COVID-19 Pandemic in GermanyClemens Kamrath, Joachim Rosenbauer, Sascha R Tittel, et al.
Pageof 1,321